Brief: Matinas Biopharma Receives Qualified Infectious Disease Product And Fast Track Designations From U.S. FDA For Mat2203
25/07/2019 12:44
July 25 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA RECEIVES QUALIFIED INFECTIOUS DISEASE
PRODUCT
(QIDP) AND FAST TRACK DESIGNATIONS FROM U.S. FDA FOR MAT2203 FOR
THE TREATMENT OF CRYPTOCOCCAL MENINGITIS
* MATINAS BIOPHARMA HOLDINGS - FDA DESIGNATED CO'S ORAL
AMPHOTERICIN B PRODUCT, AS A QUALIFIED INFECTIOUS DISEASE
PRODUCT WITH FAST TRACK STATUS
Source text for Eikon: ID:nGNX3ZDmHW
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing